Full Disclosure: This is DiagnaMed Holdings sponsored content.
new department established Diagnomed Holdings (CSE: DMED) Focus on the development and commercialization of generative AI. The division, called Health GenAI, will host a suite of products powered by GPT-4.
Health GenAI’s goal is to support the healthcare market in improving patient outcomes, efficiency and operational workflows through a suite of programs powered by artificial intelligence. Diagnomed has indicated its intention to launch at least three products from this new division this year alone.
“We are passionate about developing new generative AI-powered SaaS products that serve the needs of the healthcare sector. We are focused on commercializing three generative AI solutions to complement our generative AI brain health platform, CERVAI™,” said CEO Fabio Chianelli in announcing the announcement.
clock: DiagnaMed Brings AI to Brain Health — with Fabio Chianelli and Dr. John Kounios
The recently announced FormGPT, said to be a generative AI data collection and analysis tool for the healthcare industry, will be housed in this new division. With this product, medical professionals can create customized forms and surveys to collect relevant patient data, provide pre- and post-visit treatment feedback, monitor patient progress, and track outcomes. can be analyzed.
Meanwhile, DiagnaMed’s CERVAI will be placed under a separate division. CERVAI is the corporate generative AI brain health platform that led to the development of FormGPT.
DiagnaMed traded at $0.095 on CSE.
Full Disclosure: DiagnaMed Holdings is a customer of The Deep Dive’s parent company, Canacom Group. The author is compensated for his coverage of DiagnaMed Holdings in The Deep Dive, and The Deep Dive has full editorial rights. It is not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing any security.
as the founder of deep dive, Jay focuses on every aspect of the company. This includes not only operations, but also my role as the lead writer for The Deep Dive’s equity analysis. In addition to The Deep Dive, Jay does freelance writing for many companies and has been published in the following articles: stockhouse.com and Canna Investor Magazine Above all.
